{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:18:37Z","timestamp":1794547117009,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["LSHM-CT-2005-018734"],"award-info":[{"award-number":["LSHM-CT-2005-018734"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RESOLVE","award":["FP7-305707"],"award-info":[{"award-number":["FP7-305707"]}]},{"name":"GOA","award":["FFB180348\/36572"],"award-info":[{"award-number":["FFB180348\/36572"]}]},{"name":"Methusalem-OEC","award":["FFB190208"],"award-info":[{"award-number":["FFB190208"]}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["12V5319N"],"award-info":[{"award-number":["12V5319N"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["11E6921N"],"award-info":[{"award-number":["11E6921N"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["1802154N"],"award-info":[{"award-number":["1802154N"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The multifactorial nature of non-alcoholic fatty liver disease cannot be explained solely by genetic factors. Recent evidence revealed that DNA methylation changes take place at proximal promoters within susceptibility genes. This emphasizes the need for integrating multiple data types to provide a better understanding of the disease\u2019s pathogenesis. One such candidate gene is <jats:italic>paraoxonase-1<\/jats:italic> (<jats:italic>PON1<\/jats:italic>). Substantial interindividual differences in PON1 are apparent and could influence disease risk later in life. The aim of this study was therefore to determine the different regulatory aspects of PON1 variability and to examine them in relation to the predisposition to obesity-associated fatty liver disease.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A targeted multi-<jats:italic>omics<\/jats:italic> approach was applied to investigate the interplay between <jats:italic>PON1<\/jats:italic> genetic variants, promoter methylation, expression profile and enzymatic activity in an adult patient cohort with extensive metabolic and hepatic characterisation including liver biopsy. Alterations in PON1 status were shown to correlate with waist-to-hip ratio and relevant features of liver pathology. Particularly, the regulatory polymorphism rs705379:C\u2009&gt;\u2009T was strongly associated with more severe liver disease. Multivariable data analysis furthermore indicated a significant association of combined genetic and epigenetic <jats:italic>PON1<\/jats:italic> regulation. This identified relationship postulates a role for DNA methylation as a mediator between <jats:italic>PON1<\/jats:italic> genetics and expression, which is believed to further influence liver disease progression via modifications in PON1 catalytic efficiency.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings demonstrate that vertical data-integration of genetic and epigenetic regulatory mechanisms generated a more in-depth understanding of the molecular basis underlying the development of obesity-associated fatty liver disease. We gained novel insights into how NAFLD classification and outcome are orchestrated, which could not have been obtained by exclusively considering genetic variation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13148-021-01142-1","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T07:03:24Z","timestamp":1628838204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Sara","family":"Diels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Cuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"Tvarijonaviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Derudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Van Dijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Verrijken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc F.","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Laukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.","family":"Ceron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Vanden Berghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-7858","authenticated-orcid":false,"given":"Wim","family":"Van Hul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"1142_CR1","first-page":"1249","volume-title":"Chronic hepatitis and liver disease, Oxford textbook of public health","author":"S Francque","year":"2009","unstructured":"Francque S. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In: Damme PV, Herck KV, Michielsen P, Francque S, Shouval D, editors. Chronic hepatitis and liver disease, Oxford textbook of public health. Oxford: O.U. Press; 2009. p. 1249\u201363."},{"issue":"6","key":"1142_CR2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/obr.12407","volume":"17","author":"L Li","year":"2016","unstructured":"Li L, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17(6):510\u20139.","journal-title":"Obes Rev"},{"issue":"1","key":"1142_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"2","key":"1142_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679\u201389.","journal-title":"Hepatology"},{"key":"1142_CR5","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111:154170.","journal-title":"Metabolism"},{"key":"1142_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31446","author":"Y Fu","year":"2020","unstructured":"Fu Y, et al. Clinical features of COVID-19-infected patients with elevated liver biochemistries: a multicenter, retrospective study. Hepatology. 2020. https:\/\/doi.org\/10.1002\/hep.31446.","journal-title":"Hepatology"},{"issue":"7121","key":"1142_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","volume":"444","author":"LF Van Gaal","year":"2006","unstructured":"Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875\u201380.","journal-title":"Nature"},{"issue":"4","key":"1142_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1056\/NEJM198601233140401","volume":"314","author":"AJ Stunkard","year":"1986","unstructured":"Stunkard AJ, et al. An adoption study of human obesity. N Engl J Med. 1986;314(4):193\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"1142_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jama.1986.03380010055024","volume":"256","author":"AJ Stunkard","year":"1986","unstructured":"Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. JAMA. 1986;256(1):51\u20134.","journal-title":"JAMA"},{"issue":"9 Suppl 3","key":"1142_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/0026-0495(95)90310-0","volume":"44","author":"TI Sorensen","year":"1995","unstructured":"Sorensen TI. The genetics of obesity. Metabolism. 1995;44(9 Suppl 3):4\u20136.","journal-title":"Metabolism"},{"issue":"7","key":"1142_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/oby.2002.91","volume":"10","author":"SA Coady","year":"2002","unstructured":"Coady SA, et al. Genetic variability of adult body mass index: a longitudinal assessment in framingham families. Obes Res. 2002;10(7):675\u201381.","journal-title":"Obes Res"},{"issue":"7538","key":"1142_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature14177","volume":"518","author":"AE Locke","year":"2015","unstructured":"Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197\u2013206.","journal-title":"Nature"},{"issue":"7538","key":"1142_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature14132","volume":"518","author":"D Shungin","year":"2015","unstructured":"Shungin D, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187\u201396.","journal-title":"Nature"},{"issue":"20","key":"1142_CR14","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/hmg\/ddy271","volume":"27","author":"L Yengo","year":"2018","unstructured":"Yengo L, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. Hum Mol Genet. 2018;27(20):3641\u20139.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"1142_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/obr.13019","volume":"21","author":"S Diels","year":"2020","unstructured":"Diels S, Vanden Berghe W, Van Hul W. Insights into the multifactorial causation of obesity by integrated genetic and epigenetic analysis. Obes Rev. 2020;21(7):1\u201317.","journal-title":"Obes Rev"},{"issue":"1","key":"1142_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","volume":"17","author":"M Eslam","year":"2020","unstructured":"Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17(1):40\u201352.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"1142_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.tig.2004.06.009","volume":"20","author":"HT Bjornsson","year":"2004","unstructured":"Bjornsson HT, Fallin MD, Feinberg AP. An integrated epigenetic and genetic approach to common human disease. Trends Genet. 2004;20(8):350\u20138.","journal-title":"Trends Genet"},{"key":"1142_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-genom-090314-050057","volume":"17","author":"M Kappil","year":"2016","unstructured":"Kappil M, Wright RO, Sanders AP. Developmental origins of common disease: epigenetic contributions to obesity. Annu Rev Genomics Hum Genet. 2016;17:177\u201392.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1142_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13073-015-0225-4","volume":"7","author":"S Voisin","year":"2015","unstructured":"Voisin S, et al. Many obesity-associated SNPs strongly associate with DNA methylation changes at proximal promoters and enhancers. Genome Med. 2015;7:103.","journal-title":"Genome Med"},{"issue":"1","key":"1142_CR20","doi-asserted-by":"publisher","first-page":"20567","DOI":"10.1038\/s41598-020-77506-z","volume":"10","author":"ML Nuotio","year":"2020","unstructured":"Nuotio ML, et al. An epigenome-wide association study of metabolic syndrome and its components. Sci Rep. 2020;10(1):20567.","journal-title":"Sci Rep"},{"issue":"3","key":"1142_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4161\/epi.2.3.4897","volume":"2","author":"C Gallou-Kabani","year":"2007","unstructured":"Gallou-Kabani C, Vige A, Junien C. Lifelong circadian and epigenetic drifts in metabolic syndrome. Epigenetics. 2007;2(3):137\u201346.","journal-title":"Epigenetics"},{"issue":"2","key":"1142_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","volume":"20","author":"M Berdasco","year":"2019","unstructured":"Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2019;20(2):109\u201327.","journal-title":"Nat Rev Genet"},{"issue":"16","key":"1142_CR23","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1021\/bi047440d","volume":"44","author":"O Khersonsky","year":"2005","unstructured":"Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005;44(16):6371\u201382.","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"1142_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0014-5793(91)80962-3","volume":"286","author":"MI Mackness","year":"1991","unstructured":"Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286(1\u20132):152\u20134.","journal-title":"FEBS Lett"},{"issue":"1","key":"1142_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gene.2015.04.088","volume":"567","author":"M Mackness","year":"2015","unstructured":"Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567(1):12\u201321.","journal-title":"Gene"},{"issue":"11","key":"1142_CR26","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1074\/jbc.M512595200","volume":"281","author":"M Rosenblat","year":"2006","unstructured":"Rosenblat M, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006;281(11):7657\u201365.","journal-title":"J Biol Chem"},{"key":"1142_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13148-017-0336-4","volume":"9","author":"K Declerck","year":"2017","unstructured":"Declerck K, et al. Interaction between prenatal pesticide exposure and a common polymorphism in the PON1 gene on DNA methylation in genes associated with cardio-metabolic disease risk-an exploratory study. Clin Epigenet. 2017;9:35.","journal-title":"Clin Epigenet"},{"issue":"5","key":"1142_CR28","doi-asserted-by":"publisher","first-page":"e62565","DOI":"10.1371\/journal.pone.0062565","volume":"8","author":"K Huen","year":"2013","unstructured":"Huen K, et al. Associations of PON1 and genetic ancestry with obesity in early childhood. PLoS ONE. 2013;8(5):e62565.","journal-title":"PLoS ONE"},{"issue":"1","key":"1142_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/liv.12308","volume":"34","author":"S Desai","year":"2014","unstructured":"Desai S, et al. Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. Liver Int. 2014;34(1):110\u20137.","journal-title":"Liver Int"},{"issue":"1","key":"1142_CR30","doi-asserted-by":"publisher","first-page":"dvv003","DOI":"10.1093\/eep\/dvv003","volume":"1","author":"K Huen","year":"2015","unstructured":"Huen K, et al. PON1 as a model for integration of genetic, epigenetic, and expression data on candidate susceptibility genes. Environ Epigenet. 2015;1(1):dvv003.","journal-title":"Environ Epigenet"},{"issue":"4","key":"1142_CR31","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1021\/pr400050u","volume":"12","author":"A Garcia-Heredia","year":"2013","unstructured":"Garcia-Heredia A, et al. Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach. J Proteome Res. 2013;12(4):1946\u201355.","journal-title":"J Proteome Res"},{"issue":"4","key":"1142_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12263-011-0215-0","volume":"6","author":"MF Martinez-Salazar","year":"2011","unstructured":"Martinez-Salazar MF, et al. Relationship between the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican population: a pilot study. Genes Nutr. 2011;6(4):361\u20138.","journal-title":"Genes Nutr"},{"issue":"2","key":"1142_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263\u20135.","journal-title":"Bioinformatics"},{"issue":"9","key":"1142_CR34","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Investig. 2002;109(9):1125\u201331.","journal-title":"J Clin Investig"},{"issue":"4","key":"1142_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2012.09.002","volume":"16","author":"W Shao","year":"2012","unstructured":"Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab. 2012;16(4):414\u20139.","journal-title":"Cell Metab"},{"issue":"4","key":"1142_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jhep.2008.12.016","volume":"50","author":"F Caballero","year":"2009","unstructured":"Caballero F, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009;50(4):789\u201396.","journal-title":"J Hepatol"},{"issue":"4","key":"1142_CR37","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2011.06.040","volume":"141","author":"DM Van Rooyen","year":"2011","unstructured":"Van Rooyen DM, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011;141(4):1393\u2013403.","journal-title":"Gastroenterology"},{"issue":"5","key":"1142_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","volume":"15","author":"HK Min","year":"2012","unstructured":"Min HK, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15(5):665\u201374.","journal-title":"Cell Metab"},{"issue":"4","key":"1142_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2337\/db12-0858","volume":"62","author":"G Musso","year":"2013","unstructured":"Musso G, et al. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes. 2013;62(4):1109\u201320.","journal-title":"Diabetes"},{"issue":"4772","key":"1142_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1126\/science.3529394","volume":"234","author":"MR Briggs","year":"1986","unstructured":"Briggs MR, et al. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science. 1986;234(4772):47\u201352.","journal-title":"Science"},{"issue":"2","key":"1142_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/01.ATV.20.2.516","volume":"20","author":"I Leviev","year":"2000","unstructured":"Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000;20(2):516\u201321.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Pt 2","key":"1142_CR42","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1042\/bj20021670","volume":"372","author":"S Deakin","year":"2003","unstructured":"Deakin S, et al. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position\u2014107, implicating the Sp1 transcription factor. Biochem J. 2003;372(Pt 2):643\u20139.","journal-title":"Biochem J"},{"issue":"2","key":"1142_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0021-9150(99)00379-2","volume":"150","author":"T Suehiro","year":"2000","unstructured":"Suehiro T, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis. 2000;150(2):295\u20138.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1142_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.atherosclerosis.2004.05.029","volume":"176","author":"F Osaki","year":"2004","unstructured":"Osaki F, et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis. 2004;176(2):279\u201387.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1142_CR45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/MOP.0000000000000192","volume":"27","author":"N Holland","year":"2015","unstructured":"Holland N, Lizarraga D, Huen K. Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children\u2019s environmental health. Curr Opin Pediatr. 2015;27(2):240\u20137.","journal-title":"Curr Opin Pediatr"},{"issue":"48","key":"1142_CR46","doi-asserted-by":"publisher","first-page":"34287","DOI":"10.1074\/jbc.R113.512517","volume":"288","author":"A Blattler","year":"2013","unstructured":"Blattler A, Farnham PJ. Cross-talk between site-specific transcription factors and DNA methylation states. J Biol Chem. 2013;288(48):34287\u201394.","journal-title":"J Biol Chem"},{"key":"1142_CR47","doi-asserted-by":"publisher","first-page":"145754","DOI":"10.1155\/2012\/145754","volume":"2012","author":"M Obika","year":"2012","unstructured":"Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754.","journal-title":"Exp Diabetes Res"},{"issue":"1","key":"1142_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.atherosclerosis.2005.11.036","volume":"189","author":"J Yamada","year":"2006","unstructured":"Yamada J, et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 2006;189(1):198\u2013205.","journal-title":"Atherosclerosis"},{"issue":"7","key":"1142_CR49","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/MEG.0b013e328354044a","volume":"24","author":"DZ Banderas","year":"2012","unstructured":"Banderas DZ, et al. gamma-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol. 2012;24(7):805\u201310.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1142_CR50","doi-asserted-by":"publisher","first-page":"362147","DOI":"10.1155\/2012\/362147","volume":"2012","author":"RD Zheng","year":"2012","unstructured":"Zheng RD, et al. Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2012;2012:362147.","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"1142_CR51","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1(4):312\u201328.","journal-title":"JHEP Rep"},{"issue":"9","key":"1142_CR52","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1161\/01.ATV.19.9.2214","volume":"19","author":"RC Sorenson","year":"1999","unstructured":"Sorenson RC, et al. Human serum paraoxonase\/arylesterase\u2019s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids\u202f: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999;19(9):2214\u201325.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1142_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cca.2014.09.016","volume":"439","author":"A Gugliucci","year":"2015","unstructured":"Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta. 2015;439:5\u201313.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"1142_CR54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nsmb767","volume":"11","author":"M Harel","year":"2004","unstructured":"Harel M, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11(5):412\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"1142_CR55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/VHRM.S165173","volume":"14","author":"N Shunmoogam","year":"2018","unstructured":"Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018;14:137\u201343.","journal-title":"Vasc Health Risk Manag"},{"issue":"11","key":"1142_CR56","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1194\/jlr.M600297-JLR200","volume":"47","author":"L Gaidukov","year":"2006","unstructured":"Gaidukov L, et al. The 192R\/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006;47(11):2492\u2013502.","journal-title":"J Lipid Res"},{"issue":"4","key":"1142_CR57","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.bcp.2004.08.027","volume":"69","author":"LG Costa","year":"2005","unstructured":"Costa LG, et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69(4):541\u201350.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"1142_CR58","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.cgh.2012.06.019","volume":"10","author":"SM Francque","year":"2012","unstructured":"Francque SM, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10(10):1162\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1142_CR59","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","volume":"63","author":"S Francque","year":"2015","unstructured":"Francque S, et al. PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol. 2015;63(1):164\u201373.","journal-title":"J Hepatol"},{"issue":"4","key":"1142_CR60","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/ajcn\/41.4.810","volume":"41","author":"HC Lukaski","year":"1985","unstructured":"Lukaski HC, et al. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985;41(4):810\u20137.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"1142_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.ejcn.1601254","volume":"55","author":"P Deurenberg","year":"2001","unstructured":"Deurenberg P, et al. The validity of predicted body fat percentage from body mass index and from impedance in samples of five European populations. Eur J Clin Nutr. 2001;55(11):973\u20139.","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"1142_CR62","first-page":"187","volume":"17","author":"K van der Kooy","year":"1993","unstructured":"van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord. 1993;17(4):187\u201396.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"7","key":"1142_CR63","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"1142_CR64","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"A American Diabetes","year":"2020","unstructured":"American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14\u201331.","journal-title":"Diabetes Care"},{"issue":"4","key":"1142_CR65","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11901-019-00500-1","volume":"18","author":"RK Pai","year":"2019","unstructured":"Pai RK. NAFLD histology: a critical review and comparison of scoring systems. Curr Hepatol Rep. 2019;18(4):473\u201381.","journal-title":"Curr Hepatol Rep"},{"issue":"11","key":"1142_CR66","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/apm.12742","volume":"125","author":"A Rastogi","year":"2017","unstructured":"Rastogi A, et al. Non-alcoholic fatty liver disease\u2014histological scoring systems: a large cohort single-center, evaluation study. APMIS. 2017;125(11):962\u201373.","journal-title":"APMIS"},{"issue":"6","key":"1142_CR67","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321.","journal-title":"Hepatology"},{"issue":"5","key":"1142_CR68","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751\u20139.","journal-title":"Hepatology"},{"issue":"24","key":"1142_CR69","doi-asserted-by":"publisher","first-page":"24946","DOI":"10.1007\/s11356-019-05696-9","volume":"26","author":"M Del Carmen Xotlanihua-Gervacio","year":"2019","unstructured":"Del Carmen Xotlanihua-Gervacio M, et al. Relationship between internal and external factors and the activity of PON1. Environ Sci Pollut Res Int. 2019;26(24):24946\u201357.","journal-title":"Environ Sci Pollut Res Int"},{"key":"1142_CR70","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev.med.54.101601.152421","volume":"54","author":"LG Costa","year":"2003","unstructured":"Costa LG, et al. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med. 2003;54:371\u201392.","journal-title":"Annu Rev Med"},{"key":"1142_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2019.07.010","volume":"73","author":"A Mahrooz","year":"2019","unstructured":"Mahrooz A, et al. The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: the missing link between environmental and genetic regulation. Clin Biochem. 2019;73:1\u201310.","journal-title":"Clin Biochem"},{"key":"1142_CR72","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1186\/1471-2164-15-860","volume":"15","author":"MJ Bonder","year":"2014","unstructured":"Bonder MJ, et al. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genom. 2014;15:860.","journal-title":"BMC Genom"},{"issue":"Pt 1","key":"1142_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.envint.2018.08.044","volume":"121","author":"K Huen","year":"2018","unstructured":"Huen K, et al. PON1 DNA methylation and neurobehavior in Mexican\u2013American children with prenatal organophosphate exposure. Environ Int. 2018;121(Pt 1):31\u201340.","journal-title":"Environ Int"},{"key":"1142_CR74","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1186\/s12864-015-1847-z","volume":"16","author":"A Koch","year":"2015","unstructured":"Koch A, et al. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. BMC Genom. 2015;16:636.","journal-title":"BMC Genom"},{"key":"1142_CR75","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4939-2715-9_13","volume":"1315","author":"J Roessler","year":"2015","unstructured":"Roessler J, Lehmann U. Quantitative DNA methylation analysis by pyrosequencing(R). Methods Mol Biol. 2015;1315:175\u201388.","journal-title":"Methods Mol Biol"},{"key":"1142_CR76","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/1471-2105-11-587","volume":"11","author":"P Du","year":"2010","unstructured":"Du P, et al. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinform. 2010;11:587.","journal-title":"BMC Bioinform"},{"issue":"1","key":"1142_CR77","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate\u2013phenol\u2013chloroform extraction. Anal Biochem. 1987;162(1):156\u20139.","journal-title":"Anal Biochem"},{"issue":"4","key":"1142_CR78","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"6","key":"1142_CR79","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1074\/jbc.275.6.3957","volume":"275","author":"H Jakubowski","year":"2000","unstructured":"Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000;275(6):3957\u201362.","journal-title":"J Biol Chem"},{"issue":"10","key":"1142_CR80","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/ijms17101733","volume":"17","author":"H Skovierova","year":"2016","unstructured":"Skovierova H, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. 2016;17(10):1733.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1142_CR81","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1194\/jlr.M400511-JLR200","volume":"46","author":"DI Draganov","year":"2005","unstructured":"Draganov DI, et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46(6):1239\u201347.","journal-title":"J Lipid Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-021-01142-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T08:04:47Z","timestamp":1628841887000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-021-01142-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1186\/s13148-021-01142-1","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A written informed consent was obtained from each patient. The complete study protocol was performed according to the Declaration of Helsinki and approved by the Ethics Committee of the Antwerp University Hospital (EU consortium reference 6\/25\/125, Belgian registration number B30020071389). All authors had access to the study data and had reviewed and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LVG is a member of District 57 Speakers Bureau and has a professional relationship with NovoNordisk and AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}